Statin-Associated Muscle Symptoms in a Patient on a CYP3A4 Inhibitor
A 62-year-old woman with type 2 diabetes, hypertension, and prior MI is on atorvastatin 80 mg daily, metoprolol, lisinopril, metformin, and aspirin. She presents with 2 weeks of diffuse proximal muscle aching and dark urine. Labs: CK 12,000 U/L (baseline 120), creatinine rising from 0.9 to 1.6 mg/dL, potassium 6.1 mEq/L, and she reports starting "a new antibiotic for a chest infection" 3 weeks ago - the record shows clarithromycin. Urine dipstick is positive for blood without RBCs.
1. What is the diagnosis, and which drug interaction explains it?
Read the worked answer
Rhabdomyolysis with acute kidney injury (CK 12,000, dark urine, dipstick blood without RBCs = myoglobinuria, rising creatinine, hyperkalemia). The precipitant is a CYP3A4 interaction: atorvastatin is a CYP3A4 substrate; clarithromycin is a strong CYP3A4 inhibitor. Coadministration markedly raises atorvastatin exposure, causing myopathy/rhabdomyolysis. Additional risk factors: high-dose statin (80 mg), age, diabetes, and possible renal impairment. Other statins with less CYP3A4 dependence (rosuvastatin, pravastatin, pitavastatin) would be safer with macrolides. Metformin and lisinopril are not the cause, though lisinopril can contribute to hyperkalemia and AKI.
2. List immediate management steps, including drug discontinuation and supportive care.
Read the worked answer
- Stop atorvastatin and clarithromycin immediately. 2) Aggressive IV fluid resuscitation (normal saline) to maintain urine output ~200–300 mL/h and prevent pigment nephropathy, monitoring for volume overload. 3) Treat hyperkalemia (K 6.1): calcium gluconate if ECG changes, insulin/glucose, and a potassium binder; stop lisinopril temporarily and avoid potassium-sparing agents. 4) Monitor electrolytes, creatinine, CK, and urine output; consider urine alkalinization only if severe. 5) Avoid nephrotoxins (NSAIDs, contrast). 6) Consider renal replacement therapy if refractory hyperkalemia, acidosis, or oliguria. 7) Once stable, reintroduce a statin cautiously - use a non-CYP3A4 statin (rosuvastatin or pravastatin) at a low dose, or withhold until CK normalizes, and monitor.
3. How would you prevent recurrence and counsel the patient about future antibiotic choices?
Read the worked answer
Document statin-associated rhabdomyolysis as an adverse drug reaction. For future respiratory infections, choose antibiotics that do not inhibit CYP3A4 (e.g., amoxicillin, doxycycline, or a respiratory fluoroquinolone with awareness of its own interactions) or, if a macrolide is needed, temporarily hold the statin during the course. If a statin is restarted, prefer rosuvastatin or pravastatin (minimal CYP3A4 metabolism) and start low. Counsel the patient to report muscle pain, weakness, or dark urine promptly, to tell every prescriber/pharmacist they take a statin, and to avoid grapefruit juice and other CYP3A4 inhibitors. Reinforce diabetes and blood pressure control and arrange follow-up labs (CK, creatinine, potassium) after discharge.